Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Friday, July 4, 2025 in observance of the Fourth of July holiday.  Have a healthy, happy holiday.

Hide
Quest Diagnostics

BRCA1 and BRCA2 Testing When a Familial Variant is Reported

2023 BRCA  Symposium, The 9th International Symposium on Hereditary Breast and Ovarian Cancer

Montreal, Canada May 2-5, 2023

Poster presentation: BRCA1 and BRCA2 Testing When a Familial Variant is Reported

Authors: Terhaar C, Johnson R, Brickl A, Hawkins D, Martz J, Fesko Y

Specialties: Oncology, Genetics

Related content

Conference Presentation
Breast Cancer Cohort of the Comprehensive Outcomes for After Cancer Health (COACH) Study: Study+D124 Protocol
Test FAQ
BRCA1 and BRCA2 Deletion Duplication
Test FAQ
BRCA Panel Plus
On-Demand Webinar
Hereditary Cancer Care Starts in Primary Care
On-Demand Webinar
Innovations within Precision Oncology Evolution of a Biomarker a Case Study of KRAS-G12C

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.